Previous 10 | Next 10 |
MEI Pharma ([[MEIP]] +6.4%) has announced that the Phase 1b trial arm exploring zandelisib in combination with BeiGene's Brukinsa (zanubrutinib) has completed the safety evaluation stage in patients with B-cell malignancies and is expanding into disease specific B-cell malignancy cohorts.Anti...
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update - Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies - - MEI provi...
MEIP's pracinostat is a disaster; but zandelisib has always been its core asset. If all goes well, zandelisib may be in the market for r/r FL by 2021. Kyowa Kirin's investment in the molecule gives us confidence. For further details see: MEI Pharma: Give It Another Chanc...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into MEI Pharma, Inc. (NasdaqGS: MEIP). From August 2017, the Company repeatedly touted ...
MEI Pharma (MEIP): FQ1 GAAP EPS of -$0.13 misses by $0.06.Revenue of $3.83M (+230.2% Y/Y) beats by $0.77M.Cash, cash equivalents, and short-term investments of $176.1MPress Release For further details see: MEI Pharma EPS misses by $0.06, beats on revenue
MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights --Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment-- --MEI Starts Second Fiscal Quarter 2021 with $176.1 Million in Cash-- PR Newswire SAN...
MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences PR Newswire SAN DIEGO, Nov. 9, 2020 SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies ...
Kyowa Kirin (KYKOF) and MEI Pharma (MEIP) have dosed the first patient in Phase 2 study of zandelisib (ME-401) for the treatment of indolent B-cell non-Hodgkin's lymphoma (iNHL) without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström's macroglobulinemia in...
Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma PR Newswire TOKYO and SAN DIEGO, Oct. 2, 2020 TOKYO and SAN DIEGO , Oct. 2, 2020 /PRNewswire/ -...
The following slide deck was published by MEI Pharma, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...